false 0001178879 0001178879 2023-12-02 2023-12-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Date of Report (Date of earliest event reported): December 2, 2023



(Exact Name of Registrant as Specified in Its Charter)







(State or Other Jurisdiction

of Incorporation)



File Number)


(I.R.S. Employer

Identification No.)


47 Hulfish Street, Princeton, New Jersey 08542

(Address of Principal Executive Offices, and Zip Code)



Registrant’s Telephone Number, Including Area Code


(Former Name or Former Address, if Changed Since Last Report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)  

Name of each exchange on which registered

Common Stock Par Value $0.01   FOLD   Nasdaq


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements s of Certain Officers.


On December 2, 2023, Amicus Therapeutics, Inc. (the “Company”), determined that John F. Crowley, Executive Chairman of the Board of Directors (the “Board”) of the Company, following the successful global approvals of Pombiliti™ + Opfolda™, would conclude his service from employment and his service on the Board, effective March 4, 2024. A copy of the press release announcing Mr. Crowley’s end of service is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Mr. Crowley joined the Board in August 2004 and Company as an employee in January 2005. Since that time he has served the Company in various senior capacities (including as Chief Executive Officer prior to August 2022 and presently as Executive Chairman). Mr. Crowley’s end of service is not the result of any disagreement with the Company.


The Company wishes to thank Mr. Crowley for the countless contributions he has made to the Company over his nearly two decades of service and the integral role he has played in bringing life changing treatments to members of the Fabry and Pompe communities.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits:


Exhibit No. Description
99.1 Press Release, dated December 5, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)





Signature Page


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 5, 2023 By: /s/ Ellen S. Rosenberg
  Name: Ellen S. Rosenberg
  Title: Chief Legal Officer and Corporate Secretary




Exhibit 99.1



Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO


Crowley To Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus


Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors


PRINCETON, NJ, December 5, 2023 – Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnology Innovation Organization, effective March 4, 2024. Michael Raab, Lead Independent Director, will become the Chairman of the Amicus Board of Directors. BIO is based in Washington, DC and is the world’s largest biotechnology policy and advocacy association, representing the entire biotechnology industry, with over 1,200 member organizations worldwide.


Mr. Crowley joined Amicus in 2005 and served as Chairman and Chief Executive Officer until 2022, when he transitioned to his current role as Executive Chairman. Under Mr. Crowley’s leadership, Amicus has grown from a five-person early-stage start-up to a multi-billion dollar, publicly traded, commercial organization with two marketed therapies and over 500 employees in 21 countries around the world, treating thousands of people living with rare and devastating diseases.


“It has been an extraordinary journey and honor to have built this company and lead the Amicus team of passionate entrepreneurs,” said John F. Crowley, Executive Chairman of Amicus Therapeutics, Inc. “Over the past nearly two decades, together we have faced adversity, achieved much success, and most importantly, created an enduring legacy of hope for people living with rare diseases around the world. I have the utmost confidence in Bradley, the Board, and the entire Amicus team to lead Amicus into the future as a leading global, patient focused rare disease biotechnology company.”


“I want to extend our deepest gratitude to John for building a successful and growing company around a noble and inspirational mission. I also want to thank John personally for over two decades of mentorship, partnership, and friendship,” said Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc. “He has been instrumental in leading Amicus from a great idea to a global biotechnology company with two approved therapies for people living with rare diseases. John is the ideal candidate to lead BIO at such an important time for our industry, and we all will benefit from his continued visionary leadership.”


Michael Raab, Amicus’ Lead Independent Director, said, “On behalf of the Board of Directors and the company, we thank John for his outstanding leadership and commitment to those living with rare and devastating diseases. In his new role at BIO he will continue to expand our shared mission to alleviate human suffering at a critical time for the Biotechnology Industry. John and I have worked together for the better part of 20 years, and I am personally grateful for his pioneering efforts of inventing, innovating, and advocating on behalf of those in need. Under Bradley’s leadership, a new era for Amicus begins and is well positioned to deliver on its promise to patients and shareholders and I have great confidence in our future.”


About Amicus Therapeutics


Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.









Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations


(609) 662-3809



Amicus Therapeutics

Diana Moore

Head of Global Corporate Communications


(609) 662-5079